MarketResearch.biz delivers in-depth insights on the global cerebral malaria therapeutics market in its upcoming report titled, “Global Cerebral Malaria Therapeutics Market Trends, Applications, Analysis, Growth, and Forecast: 2018 to 2027”. The cerebral malaria therapeutics market is estimated to register a CAGR of X.X% in terms of value during forecast period 2018–2027. The report offers in-depth insights, revenue details, and other vital information regarding the target market, and the various trends, drivers, restraints, opportunities, and threats till 2027. The report offers insightful and detailed information regarding the various key players operating in the market, their financials, supply chain trends, technological innovations, key developments, apart from future strategies, acquisitions & mergers, and market footprint. The global cerebral malaria therapeutics market report has been segmented on the basis of drug class, distribution channel, and region.
Malaria is a mosquito-borne infectious disease, which affects humans as well as animals and is caused by single-celled microorganisms known as parasitic protozoan. Malaria is typically transmitted from human to human through the bite of an infected Anopheles (female) mosquito. Symptoms of malaria include fever, headache, fatigue, muscle pain, diarrhea, anemia, and vomiting. Apart from causes such as yellow skin and seizures, severe stage of malaria can cause coma or death as well. Cerebral malaria is a form of severe malaria which arises from infection with the protozoan parasite Plasmodium falciparum. Cerebral malaria has high mortality rate and can cause various complications in the neurology. Cerebral malaria can cause severe central nervous system (CNS) manifestations such as impaired consciousness, delirium, abnormal neurological signs, etc. Patients with cerebral malaria mostly manifest neurological symptoms such as nystagmus, opisthotonus, etc.
Increasing prevalence of malaria, especially in emerging countries, low-cost and easy availability of drugs are major factors anticipated to boost growth of the global cerebral malaria therapeutic market during the forecast period. In addition, increasing adoption of novel drugs and treatment, and constantly increasing innovation in drugs by carrying out R&D activities.
However, cut-throat competition among major market players, lack of awareness about proper medication or incorrect self-diagnosis, lack of awareness about available medicines among rural population in developing economies are factors that may challenge growth of the global market.
North America market is dominating in the global cerebral malaria therapeutics market in terms of revenue, followed by Europe. The US market is expected to contribute higher share to North America market during the forecast period. Asia Pacific market is expected to witness strong growth during the forecast period owing to increasing incidence of malaria, rising healthcare infrastructure, and increasing government investments for R&D activities. The cerebral malaria therapeutics market in countries such as China, India, and Brazil is projected to expand at high growth rate during the forecast period due to increase in awareness among the population about malaria disease and its available treatments.
Global Cerebral Malaria Therapeutics Market Segmentation:
Global cerebral malaria therapeutics market segmentation by drug class:
- Tetracycline antibiotics
- Analgesics & pain relievers
Global cerebral malaria therapeutics market segmentation by distribution channel:
- Drug store
- Hospital pharmacies
- Retail pharmacies
- Online pharmacies
Global cerebral malaria therapeutics market segmentation by region:
- North America
- Asia Pacific
- Latin America
- Middle East & Africa
Attribute Report Details Market Size Ask For Market Size Growth Rate Ask For Growth Rate Key Companies Ask For Companies Report Coverage Revenue analysis, Competitive landscape, Key company analysis, Market Trends, Key segments, Distribution Channel, Market Dynamics, COVID-19 Impact Analysis and more… Historical Data Period 2015-2020 Base Year 2022 Forecast Period 2022-2031 Region Scope North America, Europe, Asia-Pacific, South America, Middle East & Africa Country Scope United States, Canada and Mexico, Germany, France, UK, Russia and Italy, China, Japan, Korea, India and Southeast Asia, Brazil, Argentina, Colombia etc.Saudi Arabia, UAE, Egypt, Nigeria and South Africa Revenue in US$ Mn
- Que Pharma Pvt. Ltd.
- Cipla, Inc.
- Ipca Laboratories Ltd.
- Sun Pharmaceutical Industries Ltd.
- Guilin Pharmaceutical Co. Ltd.
- Novartis AG
- Mylan Labs
- Ajanta Pharma
- Astra Zeneca plc
Request for TOC
Why Choose Us
- 360 Degree Approach
- Growth Consulting
- 24/7 Research Support
- Comprehensive-Level of Customization
- Comprehensive-Level of Customization
- Competitive Intelligence
- Single-Country/ Region Intelligence
- Post-Sale Service Assistance
- Access to Lead Analysts
- Available in PDF, Excel, Word/ PPT
Request for Customization
Don't just take our word. We are trusted by these great companies!